Valeant's Ticking Clock to File Its Financials: Dates to Watch

Valeant Pharmaceuticals International Inc., the drugmaker at the center of a pricing scandal and mounting worries over its $32 billion debt load, has six weeks before it must file its delayed 2015 financial statements. Pressure ratcheted up this week when the company received a notice of default from bondholders that accelerated the deadline by four days.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.